BRITTANY HEADY: Open Payments
NPI 1922345214 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$837 in 43 payments from 9 companies in 2025. Trend: 2023 $795 · 2024 $549 · 2025 $837
Food & beverage: $837
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 14 | $304 |
| Otsuka America Pharmaceutical, Inc. | 8 | $135 |
| Travere Therapeutics, Inc. | 9 | $117 |
| Vifor Pharma, Inc. | 3 | $64 |
| Calliditas Therapeutics US Inc. | 2 | $59 |
| Novartis Pharmaceuticals Corporation | 2 | $51 |
| Amgen Inc. | 2 | $48 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $38 |
| AKEBIA THERAPEUTICS INC | 1 | $20 |
Products named: FARXIGA, JYNARQUE, Veltassa, TARPEYO, TAVNEOS, JARDIANCE, Vanrafia, VOYXACT.
Industry payments across MO — which companies pay providers there.
